-
Mashup Score: 1
CHICAGO — The addition of nivolumab vs. brentuximab vedotin to AVD chemotherapy significantly reduced the risk for disease progression and disease-related death among adults with previously untreated advanced classic Hodgkin lymphoma.Results of the randomized phase 3 SWOG S1826 trial, presented at ASCO Annual Meeting, showed a 52% improvement in PFS with the nivolumab (Opdivo, Bristol Myers
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 12022 D&I - Agenda | AcademyHealth - 1 year(s) ago
Event (Re)Building Better Systems: Being Proactive, Nimble, and Responsive Explore the Full Online Agenda » Explore the Sessions by Tracks » This page was last updated on December 1, 2022 Sunday, December 11, 2022 Time Activity 7:00 AM – 5:00 PM Registration 1:00 PM – 4:30 PM Pre-Conference Workshops Monday,…
Source: academyhealth.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
.@NIH, @AcademyHealth: Looking forward to #plenary session: Rethinking #Implementation #Partner Perspectives t #DIScience22 Tuesday, Dec-13 at 4:15pm ET. #ImpSci @ImplementSci @implementEIC @ImplementCollab @NCI_ImplSci @ImpScience @NIH_NHLBI @ONC_HealthIT https://t.co/PExKZafPZU https://t.co/uDyVW02IXk
-
-
Mashup Score: 1
General Sessions Plenary Scientific Session Clinical Trials, Biological, Adults, Lymphomas, Non-Hodgkin Lymphoma, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Immune Mechanism, B Cell Lymphoma, Diseases, Therapies, Lymphoid Malignancies, Biological Processes, Study Population Frederick L. Locke, MD1, David B. Miklos, MD, PhD2,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Paradigm shift for high risk DLBCL in 1st relapse. Join me Sunday 12/12/21 #ASH2021 for the #plenary session - ZUMA-7 study being presented with NEJM publication released today. I am just so incredibly happy for our pts. https://t.co/1W0KvS6B0B @JTCancerCenter @HMHSchoolofMed
-
-
Mashup Score: 0
General Sessions Plenary Scientific Session Clinical Trials, Biological, Adults, Lymphomas, Non-Hodgkin Lymphoma, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Immune Mechanism, B Cell Lymphoma, Diseases, Therapies, Lymphoid Malignancies, Biological Processes, Study Population Frederick L. Locke, MD1, David B. Miklos, MD, PhD2,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Paradigm shift for high risk DLBCL in 1st relapse. Join me Sunday 12/12/21 #ASH2021 for the #plenary session - ZUMA-7 study being presented with NEJM publication released today. I am just so incredibly happy for our pts. https://t.co/1W0KvS6B0B https://t.co/xhcr85xCzh
-
-
Mashup Score: 17
This podcast discusses the results and implications of a recent study on gender bias in speaker introductions at an international oncology conference. This JCO Podcast provides observations and commentary on the JCO article “Evaluating Unconscious Bias: Speaker Introductions at an International Oncology Conference” by Duma et al. My name is Dr. Tatiana Prowell. I am an Associate Professor of…
Categories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO21. I received sev texts at once asking me to tweet reminder not to call panelists by 1st name in formal settings (eg @ASCO #Plenary). Pls say Dr_, Mr_, Ms_. I did this brief @ASCO_pubs JCO podcast explaining why it matters: https://t.co/YAAY3idJvP cc @HemOncWomenDocs
-
-
Mashup Score: 9
Original Article from The New England Journal of Medicine — Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
#ASCO21. #Plenary. Tutt et al: OlympiA trial in patients with high-risk early HER2- #breastcancer (ER+/HER2- or #TNBC) & or germline #BRCA1 or #BRCA2 mutation. https://t.co/rzNHpsMtz0. #bcsm #gencsm https://t.co/VXLaTxTXc0
-
The 👆🏾#ASCO21 presentation 📺 #plenarysession also had the @NEJM last slide publication 🎤 drop. https://t.co/l9Oe4h9Roj @OncoAlert @ASCO
-
-
Mashup Score: 2High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? - 3 year(s) ago
The indications for adjuvant vascular endothelial growth factor–tyrosine kinase inhibitor (VEGF-TKI) agents after curative intent nephrectomy for rena…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
A nice summary of the past approaches to adjuvant therapy for high risk #RCC, pending new therapeutic options as we will see later today #Plenary #ASCO2021 @u_capitanio @GFallara_MD @MyUniSR @SanRaffaeleMI https://t.co/lYsLtOeL0K
-
-
Mashup Score: 1Paper: Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance) - 3 year(s) ago
General Sessions Plenary Scientific Session Adult, Study Population Bhavana Bhatnagar, DO1, Qiuhong Zhao, MS2,3*, James L. Fisher, PhD4*, Jessica Kohlschmidt, PhD5, Krzysztof Mrózek, MD, PhD5, Deedra Nicolet, MS5*, Shelley Orwick, BS6*, James S. Blachly, MD5,7, Alice S. Mims, MD5, Christopher J. Walker, PhD8, Andrew J Carroll, PhD9, Bayard L. Powell,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
6 Poor Treatment Outcomes of Young (<60 Years) African American Patients (Pts) Diagnosed with Acute Myeloid Leukemia (AML) (Alliance) #ASH20 #plenary https://t.co/5CdKwTuz16 #ASHFromHome #ASHKudos #ASHTogether #ASHHaiku #IRunForASH #IWalkForASH
-
-
Mashup Score: 3
General Sessions Plenary Scientific Session cell division, cellular interactions, Biological Processes, epigenetics, hematopoiesis, pathways, signal transduction Kerstin B Kaufmann, PhD1, Andy G.X. Zeng, BSc2, Etienne Coyaud3*, Laura Garcia Prat, PhD, BSc, MSc3, Efthymia Papalexi, BA4,5*, Estelle MN Laurent3*, Michelle Chan-Seng-Yue1,6*, Olga I. Gan,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
5 Divergent Levels of CD112 and INKA1 Define a Subset of Human Hematopoietic Stem Cells That Resists Regenerative Stress to Preserve Stemness #ASH20 #plenary https://t.co/jLlg02UEqI #ASHFromHome #ASHKudos #ASHTogether #ASHFromHome #ASHKudos #ASHTogether #ASHHaiku #IRunForASH
-
-
Mashup Score: 3Paper: BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL - 3 year(s) ago
General Sessions Plenary Scientific Session Diseases, Lymphoma (any), Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, Biological Processes, Lymphoid Malignancies, pathways, signal transduction Min Xia1, Liron David, PhD2*, Matthew Teater, PhD3*, Ozlem Onder, PhD, MSc4*, Kojo S. J. Elenitoba-Johnson, MD5, Lorena Fontan, PhD6, Hao Wu, PhD2* and Ari Melnick,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
3 BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL #ASH20 #plenary https://t.co/H1sw2AtwvW #ASHFromHome #ASHKudos #ASHTogether #lymsm #ASH2020
-
Nivolumab regimen improves outcomes in previously untreated classic Hodgkin lymphoma. Alex Herrera, MD, of @cityofhope tells Healio the findings are 'a huge advance.' #ASCO23 #plenary #Opdivo #Adcetris @bmsnews https://t.co/W571zillsQ